<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053893</url>
  </required_header>
  <id_info>
    <org_study_id>XHASB-001</org_study_id>
    <nct_id>NCT05053893</nct_id>
  </id_info>
  <brief_title>Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome</brief_title>
  <official_title>A Randomized, Parallel Controlled Trial of Roxadustat Combined withSacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Qingdao University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized and parallel controlled trial design of comparing the new treatment group of&#xD;
      Roxadustat combined with Sacubitril Valsartan Sodium Tablets with the traditional treatment&#xD;
      group of recombinant human erythropoietin (EPO) combined with ACEI or ARB in Chinese patients&#xD;
      with cardiorenal anemia syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 22, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of hemoglobin level before and after treatment</measure>
    <time_frame>Day0-Day90</time_frame>
    <description>By detecting blood routine,calculate the changes of hemoglobin.Change value of hemoglobin level(g/L) = baseline hemoglobin level(g/L) - hemoglobin level after treatment(g/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of ejection fraction before and after treatment</measure>
    <time_frame>Day0-Day90</time_frame>
    <description>Cardiac ejection fraction was measured by cardiac ultrasound before and after treatment，and change of cardiac ejection fraction(%) = baseline cardiac ejection fraction level(%) - post-treatment cardiac ejection fraction level(%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of acute heart failure, acute myocardial infarction, severe hyperkalemia and severe anemia during treatment</measure>
    <time_frame>Day0-Day90</time_frame>
    <description>Incidence rate = number of patients with the events/ total number of patients included in the study in this group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cardio-Renal Syndrome</condition>
  <arm_group>
    <arm_group_label>New treatment group(Roxadustat combined with Sacubitril Valsartan Sodium Tablets)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roxadustat(FibroGen, China), 100mg (45-60kg) or 120mg (≥ 60kg) each time, three times a week, orally on an empty stomach in the morning. The initial dose of Sacubitril Valsartan Sodium Tablets(Novartis, China) is 50mg, once a day, taken on an empty stomach in the morning, and gradually titrated from the minimum dose to the maximum tolerated dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional treatment group(EPO combined with ACEI or ARB )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human erythropoietin (SEBOR, 10000 units / Branch) was injected subcutaneously once a week; Perindopril tablets (Servier, China), taken on an empty stomach, gradually titrated from the minimum dose to the maximum tolerated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat;Sacubitril Valsartan Sodium Tablets;</intervention_name>
    <description>Select the appropriate dose according to the patient's situation</description>
    <arm_group_label>New treatment group(Roxadustat combined with Sacubitril Valsartan Sodium Tablets)</arm_group_label>
    <other_name>Entresto®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPO; ACEI / ARB</intervention_name>
    <description>Select the appropriate ACEI /ARB according to the subject's situation or follow its previous medication</description>
    <arm_group_label>Traditional treatment group(EPO combined with ACEI or ARB )</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed as regular dialysis patients with cardiorenal anemia syndrome&#xD;
&#xD;
          -  Hemoglobin 60-110g / L (twice with an interval of at least 4 days);&#xD;
&#xD;
          -  Volunteered to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anemia caused by diseases other than CKD&#xD;
&#xD;
          -  Malignant tumors&#xD;
&#xD;
          -  Active liver disease&#xD;
&#xD;
          -  Rheumatic immune diseases in active stage&#xD;
&#xD;
          -  Hereditary or idiopathic angioedema&#xD;
&#xD;
          -  Systolic blood pressure≥180 mmHg;diastolic blood pressure≥110 mmHg&#xD;
&#xD;
          -  Acute myocardial infarction and unstable angina pectoris&#xD;
&#xD;
          -  Severe parathyroidism&#xD;
&#xD;
          -  Active peptic ulcer&#xD;
&#xD;
          -  taking aliskiren&#xD;
&#xD;
          -  Mental disease&#xD;
&#xD;
          -  Alcohol and drug abuse&#xD;
&#xD;
          -  Allergy to test drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guangqun Xing, Doctor</last_name>
    <phone>18661802178</phone>
    <email>gqx99monash@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting Li, Master</last_name>
    <phone>18661801532</phone>
    <email>lt20080607@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nephrology, Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shangdong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gungqun Xing, Doctor</last_name>
      <phone>186661802178</phone>
      <email>gqx99monash@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Hospital of Qingdao University</investigator_affiliation>
    <investigator_full_name>Guangqun Xing,MD</investigator_full_name>
    <investigator_title>Chief physician; Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardio-Renal Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

